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See Editorial, pages 1066–1067The disease entity today widely called ‘primary biliary cirrhosis’
was ﬁrst described by Addison & Gull in 1851 [1] and Hanot in
1876 [2]. One hundred years after its ﬁrst description,
MacMahon & Thannhauser proposed the term ‘xanthomatous
biliary cirrhosis’ for this disease based on the typical xanthoma
formation with accumulation of cholesterol esters in the skin
around the eyes in association with inﬂammatory destruction
of small intrahepatic bile ductules leading to a biliary type cirrho-
sis [3]. Xanthoma formation, however, is not a very common sign
in this disorder. This may be the reason why the term ‘primary
biliary cirrhosis’, proposed one year later for the same disorder
by Ahrens et al., [4] gained wider acceptance when most patients
were presenting with advanced liver disease.
Dame Sheila Sherlock, already in 1959, opposed the term ‘pri-
mary biliary cirrhosis’ as many of her patients were free of cirrho-
sis at the time of diagnosis and the mean survival was 5 and a half
years (3–11) even for the fatal cases, whereas many asymp-
tomatic patients would survive more than 10 years [5]. The term
‘primary biliary cirrhosis’ remained an issue of concern asJournal of Hepatology 20
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license (http://creativecommons.org/licenses/by/4.0/).reﬂected by the name change proposal of Rubin, Schaffner and
Popper in 1965 with their paper ‘Primary biliary cirrhosis –
Chronic non-suppurative destructive cholangitis’ [6]. S. Sherlock
wisely commented on this new name: ‘‘. . .a better one, although
it is unlikely that it will replace the more popular, although inac-
curate, one of primary biliary cirrhosis’’ [7]. She was right, again.
And even 40 years later, the European [8] and American [9]
Clinical Practice Guidelines still used the term ‘primary biliary
cirrhosis’ even though it was an anachronism and did not accu-
rately reﬂect the natural history of disease in the vast majority
of patients as it is today.
The early diagnosis of primary biliary cirrhosis has dramati-
cally improved with the more accurate measurements of markers
of cholestasis and improvements in the detection of the classic
serologic hallmark, anti-mitochondrial antibodies. Furthermore,
the prognosis has dramatically improved with the introduction
of orthotopic liver transplantation in the 1970s and 1980s, and
of ursodeoxycholic acid (UDCA, 13–15 mg/kg daily) treatment
in the 1980s and 1990s. Today, two out of three patients diag-
nosed with primary biliary cirrhosis and treated with UDCA have
an expected survival not different from the general population
and only a minority will ever develop cirrhosis.
The pathogenesis of primary biliary cirrhosis remains enig-
matic although enormous progress has been made in unravelling
genetic, immunological and pathophysiological molecular mech-
anisms involved [10–13]. This has also led to new therapeutic
approaches which are now under evaluation [14,15].
On 23–24 May, 2014, the 2nd European Association for the
Study of the Liver (EASL) Monothematic Conference on Primary
Biliary Cirrhosis took place in Milan, Italy. On this occasion,
patient representatives from the UK and Germany, Robert
Mitchell-Thain and Ingo van Thiel, representing numerous
national patient groups from different parts of the world
requested to change the name of ‘primary biliary cirrhosis’ to15 vol. 63 j 1285–1287
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‘‘correct the inaccuracy’’ and ‘‘remove the cirrhosis stigma’’ as
well as all the misunderstanding, disadvantages and discrimina-
tions emanating from this misnomer in daily life of the patients.
This initiative was based on former discussions at a meeting with
international patient advocates and medical experts led by Raoul
Poupon of France during the EASL International Liver Congress
2014 in London, and based in part on worldwide survey by
patient support groups performed among >1200 patients with
primary biliary cirrhosis.
E-mail discussions among experts in the ﬁeld before the meet-
ing, as well as intense discussions during the EASL Monothematic
Conference in Milan with continual e-mail exchanges after the
meeting has led to the widespread view among the vast majority
of worldwide experts that; (1) the name ‘primary biliary cirrho-
sis’ should be changed [as advocated by Dame Sheila Sherlock
in 1959]. In addition, the following proposals found broad sup-
port among the discussants; (2) the acronym ‘PBC’ should be kept
if possible; (3) a simple and short term should be used (imperfec-
tion acceptable) as long as the exact pathogenesis of primary bil-
iary cirrhosis remained undeﬁned and, therefore, an ‘ideal’
replacement is not available.
In parallel with the growing patient support from Europe and
the U.S., several surveys were performed among international
experts in the ﬁeld. Among EASL-selected committee members
and senior reviewers of the EASL Guidelines for management of
cholestatic liver diseases (n = 15), 100% agreed to a name change
for primary biliary cirrhosis and 100% voted to keep the abbrevi-
ation ‘PBC’. 60% preferred ‘primary biliary cholangitis’, 20% ‘pri-
mary biliary cholangiopathy’, and 20% various other names.
Among international experts from the American Association for
the Study of Liver Disease (AASLD), Asian Paciﬁc Association for
the Study of the Liver (APASL) and EASL [outside the EASL com-
mittees] (n = 16), 88% agreed to a name change for primary bil-
iary cirrhosis and 88% voted to keep the abbreviation ‘PBC’. 56%
preferred ‘primary biliary cholangitis’, 13% ‘primary biliary
cholangiopathy’, and 38% various other names. Among Japanese
experts (n = 18), 100% agreed to a name change for primary bil-
iary cirrhosis and 78% voted to keep the abbreviation PBC. 61%
preferred ‘primary biliary cholangitis’, 28% ‘primary biliary
cholangiopathy’, and 11% various other names. Thus, considering
that imperfection was acceptable in name ﬁnding, ‘primary bil-
iary cholangitis’ found the broadest support as the new name
for PBC among experts worldwide.
Our goal, as physicians, is to help and heal our patients both
actively at the bedside but also passively in everyday social chal-
lenges as patients balance their personal lives with their clinical
needs. Our misuse of the name ‘cirrhosis’ is counterproductive to
our support and our role as physicians. We should also note that
the change of name for an autoimmune disease is not without
precedence: Wegener’s granulomatosis for example is now
known as granulomatous polyangiitis.
The proposal for a name change of primary biliary cirrhosis
to ‘primary biliary cholangitis’ was approved by the EASL
Governing Board in November 2014, by the AASLD Governing
Board in April 2015 and by the American Gastroenterological
Association (AGA) Governing Board in July 2015. A vote of
the APASL Governing Board and the United European
Gastroenterology (UEG) Governing Board was pending at the
moment this article was written, whereas support by respected
Governing Board members from both associations was provided
beforehand.1286 Journal of Hepatology 2015What are the next steps? The World Health Organization
(WHO) is asking medical professionals for the ﬁrst time to help
in the revision process of the diagnosis and symptom codes
(International Classiﬁcation of Diseases 11th Revision, ICD-11).
The medical representatives of the ‘‘Name Change Initiative for
PBC’’ – with support of the international primary biliary cirrhosis
patient groups – will take responsibility to submit the joint pro-
posal of international experts around the world for the name ‘pri-
mary biliary cholangitis’.
We are aware of the imperfection of the new simple name and
agree that alternative proposals like primary small bile duct
cholangitis, primary intrahepatic cholangitis, primary small bile
duct cholangiopathy, primary biliary/peripheral (destructive)
cholangitis, or primary cholangiohepatitis may come somewhat
closer to what we think this inﬂammatory liver disorder is about.
However, we would kindly remind all critics of the fate of Hans
Popper’s carefully chosen ‘chronic non-suppurative destructive
cholangitis’ – too difﬁcult according to the late Dame Sheila
Sherlock. It failed to reach sufﬁcient support.
‘Primary biliary cholangitis’ is a tautology (‘‘saying the same
thing twice’’), some critics say. But is that true? ‘Cholangitis’ ade-
quately describes the dense inﬂammatory inﬁltrates around
small damaged interlobular bile ductules. Recent experimental
evidence suggests that hydrophobic bile acids in bile, the major
biliary organic solutes, may play a crucial role in the initiation
of inﬂammation in primary biliary cirrhosis [16–21]. Future
research will teach us whether we have chosen a simple and,
beyond that, reasonable name.
The new term ‘primary biliary cholangitis’ will lead to
confusion in daily clinical practice with other forms of immune-
mediated cholangitis such as primary sclerosing cholangitis
(PSC), some critics say. Indeed, the term ‘cholangitis’ is a general
description of an inﬂammatory disorder of the intra- and/or
extrahepatic bile ducts as is ‘cirrhosis’ for the description of
replacement of normal liver tissue by scar tissue. The name
change for primary biliary cirrhosis offers the unique opportunity
for new awareness campaigns among medical professionals as
well as patient groups to draw more attention to immune-
mediated biliary diseases like PBC or PSC and, ultimately, their
early correct diagnosis and treatment.
From ‘cirrhosis’ to ‘cholangitis’ – the change has critical impli-
cations for patients. It removes the stigmata of cirrhosis and its
implications of alcohol abuse. It removes the stigmata of a poor
prognosis. Its removal reminds patients that they are living with
this syndrome, not dying of it. Its removal improves their oppor-
tunities in the workplace and in their everyday social lives. Thus,
we sincerely call on all medical professionals and all patients and
their families and friends worldwide to use from this moment on
the name ‘‘primary biliary cholangitis’’ for the disease known by
its abbreviation PBC! We owe this to our patients and to further
our role as caring physicians.References
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